DK1750716T3 - Behandling af T-celle-lymfom under anvendelse af 10-propargyl-10-deazaaminopterin - Google Patents
Behandling af T-celle-lymfom under anvendelse af 10-propargyl-10-deazaaminopterinInfo
- Publication number
- DK1750716T3 DK1750716T3 DK05756183T DK05756183T DK1750716T3 DK 1750716 T3 DK1750716 T3 DK 1750716T3 DK 05756183 T DK05756183 T DK 05756183T DK 05756183 T DK05756183 T DK 05756183T DK 1750716 T3 DK1750716 T3 DK 1750716T3
- Authority
- DK
- Denmark
- Prior art keywords
- cell lymphoma
- deazaaminopterin
- propargyl
- treatment
- amount
- Prior art date
Links
- 206010042971 T-cell lymphoma Diseases 0.000 title abstract 4
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 title abstract 4
- OGSBUKJUDHAQEA-WMCAAGNKSA-N pralatrexate Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 title abstract 3
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000003442 weekly effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52159304P | 2004-05-30 | 2004-05-30 | |
| PCT/US2005/019169 WO2005117891A1 (en) | 2004-05-30 | 2005-05-31 | Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1750716T3 true DK1750716T3 (da) | 2008-12-08 |
Family
ID=34971703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05756183T DK1750716T3 (da) | 2004-05-30 | 2005-05-31 | Behandling af T-celle-lymfom under anvendelse af 10-propargyl-10-deazaaminopterin |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US7939530B2 (https=) |
| EP (1) | EP1750716B1 (https=) |
| JP (1) | JP5005532B2 (https=) |
| KR (1) | KR101189693B1 (https=) |
| CN (2) | CN102824346B (https=) |
| AT (1) | ATE405272T1 (https=) |
| AU (1) | AU2005249516B2 (https=) |
| BR (1) | BRPI0510895A (https=) |
| CA (1) | CA2565968C (https=) |
| DE (1) | DE602005009176D1 (https=) |
| DK (1) | DK1750716T3 (https=) |
| ES (1) | ES2313365T3 (https=) |
| HR (1) | HRP20080569T3 (https=) |
| ME (1) | ME01087B (https=) |
| MX (1) | MXPA06013559A (https=) |
| NO (1) | NO337276B1 (https=) |
| NZ (2) | NZ576849A (https=) |
| PL (1) | PL1750716T3 (https=) |
| PT (1) | PT1750716E (https=) |
| RS (1) | RS50622B (https=) |
| SI (1) | SI1750716T1 (https=) |
| WO (2) | WO2005117891A1 (https=) |
| ZA (1) | ZA200609266B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
| US8263354B2 (en) * | 2004-05-30 | 2012-09-11 | Sloan-Kettering Institute For Cancer Research | Methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin |
| US20080188479A1 (en) * | 2004-05-30 | 2008-08-07 | Sloan-Kettering Institute For Cancer Research | Methods to Treat Cancer with 10-propargyl-10-deazaaminopterin and Methods for Assessing Cancer for Increased Sensitivity to 10-propargyl-10-deazaaminopterin |
| CA2565968C (en) | 2004-05-30 | 2013-01-08 | Sloan-Kettering Institute For Cancer Research | Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin |
| KR101335021B1 (ko) | 2007-07-31 | 2013-12-12 | 액세라인크 | 게놈 테스트의 용도 및 인지 기능 저하 치료용 케톤성 화합물 |
| US20100248249A1 (en) * | 2007-08-17 | 2010-09-30 | Allos Therapeutics, Inc. | Methods for Assessing Cancer for Increased Sensitivity to 10-Propargyl-10-Deazaaminopterin by Assessing Egfr Levels |
| US9901578B2 (en) | 2007-08-17 | 2018-02-27 | Allos Therapeutics, Inc. | Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer |
| WO2009026234A1 (en) * | 2007-08-17 | 2009-02-26 | Allos Therapeutics, Inc. | Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer |
| US9125881B2 (en) | 2008-07-03 | 2015-09-08 | Accera, Inc. | Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders |
| WO2010022277A2 (en) * | 2008-08-20 | 2010-02-25 | O'connor Owen A | Combination of 10-propargyl-10-deazaaminopterin and bortezomib for the treatment of cancers |
| US20110190305A1 (en) | 2010-02-02 | 2011-08-04 | Allos Therapeutics, Inc. | Optically Pure Diastereomers of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same |
| EP2575466B1 (en) * | 2010-06-02 | 2015-04-08 | Allos Therapeutics, Inc. | Methods for treating methotrexate-resistant disorders with 10-propargyl-10-deazaaminopterin |
| US20130178441A1 (en) * | 2010-08-10 | 2013-07-11 | Allos Therapeutics, Inc. | Methods for Extending Progression-Free Survival using 10-Propargyl-10-Deazaaminopterin |
| WO2013164856A1 (en) | 2012-05-04 | 2013-11-07 | Avra Laboratories Private Limited | A process for preparing intermediates of 10-propargyl-10-deazaaminopterin (pralatrexate) synthesis and the intermediates thereof |
| CN103274943B (zh) * | 2013-05-24 | 2015-01-21 | 苏州明锐医药科技有限公司 | 4-[1-(2-丙炔基)-3,4-二氧代正丁基]苯甲酸酯及其制备方法 |
| WO2016205203A1 (en) | 2015-06-16 | 2016-12-22 | Spectrum Pharmaceuticals, Inc. | Combination therapy using belinostat and pralatrexate to treat lymphoma |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4393064A (en) * | 1976-03-05 | 1983-07-12 | Sri International | Process and composition for treatment of leukemia and process for preparing the same |
| US4652533A (en) * | 1983-04-28 | 1987-03-24 | Pandex Laboratories, Inc. | Method of solid phase immunoassay incorporating a luminescent label |
| US4843155A (en) * | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| DE69133095T2 (de) * | 1990-11-20 | 2003-03-27 | Dade Behring Marburg Gmbh | Cyclosporin-Immunoassay |
| US5354751A (en) * | 1992-03-03 | 1994-10-11 | Sri International | Heteroaroyl 10-deazaamino-pterine compounds and use for rheumatoid arthritis |
| US5981592A (en) * | 1995-03-13 | 1999-11-09 | Loma Linda University Medical Center | Method and composition for treating cystic fibrosis |
| US6323205B1 (en) * | 1996-07-17 | 2001-11-27 | Sloan-Kettering Institute For Cancer Research | Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors |
| PT944389E (pt) * | 1996-07-17 | 2008-12-03 | Sloan Kettering Inst Cancer | Composições purificadas de 10-propargil-10-desaza-aminopterina e métodos para a sua utilização no tratamento de tumores |
| GB0128510D0 (en) * | 2001-11-28 | 2002-01-23 | Novartis Ag | Organic compounds |
| CA2565968C (en) * | 2004-05-30 | 2013-01-08 | Sloan-Kettering Institute For Cancer Research | Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin |
-
2005
- 2005-05-31 CA CA2565968A patent/CA2565968C/en not_active Expired - Lifetime
- 2005-05-31 RS RSP-2008/0470A patent/RS50622B/sr unknown
- 2005-05-31 CN CN201210342831.8A patent/CN102824346B/zh not_active Expired - Lifetime
- 2005-05-31 ZA ZA200609266A patent/ZA200609266B/xx unknown
- 2005-05-31 SI SI200530392T patent/SI1750716T1/sl unknown
- 2005-05-31 PL PL05756183T patent/PL1750716T3/pl unknown
- 2005-05-31 WO PCT/US2005/019169 patent/WO2005117891A1/en not_active Ceased
- 2005-05-31 BR BRPI0510895-0A patent/BRPI0510895A/pt not_active Application Discontinuation
- 2005-05-31 AU AU2005249516A patent/AU2005249516B2/en not_active Expired
- 2005-05-31 ME MEP-2008-310A patent/ME01087B/me unknown
- 2005-05-31 US US11/568,254 patent/US7939530B2/en active Active
- 2005-05-31 EP EP05756183A patent/EP1750716B1/en not_active Expired - Lifetime
- 2005-05-31 CN CNA2005800173160A patent/CN1960734A/zh active Pending
- 2005-05-31 DK DK05756183T patent/DK1750716T3/da active
- 2005-05-31 HR HR20080569T patent/HRP20080569T3/xx unknown
- 2005-05-31 NZ NZ576849A patent/NZ576849A/en not_active IP Right Cessation
- 2005-05-31 US US11/141,868 patent/US7622470B2/en not_active Expired - Lifetime
- 2005-05-31 PT PT05756183T patent/PT1750716E/pt unknown
- 2005-05-31 NZ NZ551082A patent/NZ551082A/en not_active IP Right Cessation
- 2005-05-31 KR KR1020117012373A patent/KR101189693B1/ko not_active Expired - Lifetime
- 2005-05-31 DE DE602005009176T patent/DE602005009176D1/de not_active Expired - Lifetime
- 2005-05-31 AT AT05756183T patent/ATE405272T1/de active
- 2005-05-31 MX MXPA06013559A patent/MXPA06013559A/es active IP Right Grant
- 2005-05-31 JP JP2007515512A patent/JP5005532B2/ja not_active Expired - Lifetime
- 2005-05-31 ES ES05756183T patent/ES2313365T3/es not_active Expired - Lifetime
- 2005-05-31 WO PCT/US2005/019170 patent/WO2005117892A1/en not_active Ceased
-
2006
- 2006-12-22 NO NO20065971A patent/NO337276B1/no unknown
-
2009
- 2009-10-21 US US12/603,117 patent/US8299078B2/en not_active Expired - Lifetime
-
2012
- 2012-10-29 US US13/663,234 patent/US20130053391A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1750716T3 (da) | Behandling af T-celle-lymfom under anvendelse af 10-propargyl-10-deazaaminopterin | |
| NO20014519L (no) | Apomorfin- og sildenafilpreparat | |
| WO2004062604A3 (en) | Treatment of cancer with 2-deoxyglucose | |
| CA2683786C (en) | Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects | |
| RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
| CY1108217T1 (el) | Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης | |
| NO20072931L (no) | Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva | |
| RU2013123646A (ru) | Комбинированная композиция | |
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| JP2002523370A5 (https=) | ||
| DK1689404T3 (da) | Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer | |
| CY1118486T1 (el) | Λαπατινιμπη για τη θεραπεια του καρκινου | |
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| DE60222383D1 (de) | Medikament zur verabreichung von amifostin und verwandten wirkstoffen | |
| AR023185A1 (es) | Tratamiento de cancer mejorado con temozolomida | |
| RU2009101026A (ru) | Применение тимозина-альфа-1 для получения лекарственного средства для лечения злокачественной меланомы на iv стадии | |
| WO2001080895A3 (en) | Methods and compositions for the treatment of cardiac indications | |
| MX2010006310A (es) | O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor. | |
| MX2012005497A (es) | Tivozanib y temsirolimus en combinacion. | |
| WO2006124573A3 (en) | Treatment of cancer with 2-deoxyglucose | |
| WO2008079818A3 (en) | Intravenous administration of water soluble analgesic formulations | |
| WO2007093519A3 (en) | Ibandronate regimen for treating metastatic bone pain | |
| TW200626172A (en) | Treatment of HIV infection | |
| RU2005114664A (ru) | Способ лечения хронического панкреатита | |
| RU2007132181A (ru) | ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ |